Abstract | BACKGROUND: Activity of the tumour-suppressor gene PTEN is reduced in different types of cancer and implicates non-responsiveness to targeted therapy. This study evaluates the gene and protein status of PTEN in salivary gland carcinomas. METHODS: RESULTS: Hemizygous deletions of PTEN were found in 35 out of 232 (15.1%) carcinomas, while homozygous deletions were observed in 17 out of 232 (7.3%) tumours. Phosphatase and tensin homologue located on chromosome 10 deletion was common in certain histological subtypes and especially homozygous deletion was associated with high-grade malignancy, lymph node metastases and unfavourable long-term prognosis (P<0.001). Loss of PTEN expression was present in 59 out of 273 (21.6%) carcinomas and was significantly correlated to genomic PTEN deletion, high-grade malignancy (P<0.001), increased tumour size (P=0.036), lymph node metastases (P=0.007) and worse disease-specific survival (P=0.002). Genomic PTEN deletion, in particular homogenous deletion (P<0.001) predominantly occurred in tumours with increased gene copy number of EGFR (60.0%) and/or amplification of HER2 (63.6%). Loss of PTEN expression was frequently found in tumours overexpressing EGFR (28.6%) and/or HER2 (52.6%). CONCLUSION: PTEN function is reduced in different types of salivary gland cancer indicating unfavourable prognosis. Its association with EGFR and HER2 signalling might affect targeted therapy.
|
Authors | T Ettl, K Baader, C Stiegler, M Müller, A Agaimy, J Zenk, T Kühnel, M Gosau, K Zeitler, S Schwarz, G Brockhoff |
Journal | British journal of cancer
(Br J Cancer)
Vol. 106
Issue 4
Pg. 719-26
(Feb 14 2012)
ISSN: 1532-1827 [Electronic] England |
PMID | 22240798
(Publication Type: Journal Article)
|
Chemical References |
- ErbB Receptors
- Receptor, ErbB-2
- PTEN Phosphohydrolase
- PTEN protein, human
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Child
- ErbB Receptors
(metabolism)
- Female
- Gene Deletion
- Humans
- Male
- Middle Aged
- PTEN Phosphohydrolase
(genetics, metabolism)
- Prognosis
- Receptor, ErbB-2
(metabolism)
- Salivary Gland Neoplasms
(genetics, metabolism, mortality, pathology)
|